ClinicalTrials.gg

Program

NVXC19

A development code. Also written as “IIV-HD + NVXC19 combination”.

Its studies are mostly in Influenza, Human, led by Sanofi.

Furthest: phase 3, since Oct 15, 20261 company-led study, 1 open or runningNext primary completion: Dec 28, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sanofi11 open or runningphase 3since Oct 15, 2026Oct 15, 2026Dec 28, 2027phase 3 · NCT07890454

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 15, 2026First study: phase 3 study in Influenza, HumanFirst studyNCT07890454 · 6,000 planned · Poland

Ahead

  1. Dec 28, 2027Primary completion: phase 3 study in Influenza, HumanNCT07890454

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07890454Influenza, Human · Poland3RecruitingDec 28, 20276,000

How it is read

Names in the registry

  • “IIV-HD + NVXC19 combination”, 1 entry

Codes read as this program: NVXC19.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.